

BIOGLAN AND STADA PARTNER TO INCREASE CAPACITY TO MEET RISING DEMAND FOR PARKINSON'S TREATMENT

- REIG JOFRE's Bioglan subsidiary in Sweden and STADA are investing EUR3 million to expand Bioglan's facilities with a highly technological production line devoted to a patented combination therapy for Parkinson's disease
- Bioglan is the exclusive manufacturer for the European market of the medicine, which is marketed by STADA as a treatment indicated for advanced Parkinson's disease
- The therapy has already been approved in several European countries and is currently marketed by STADA in Nordic countries, Germany, Austria, and Slovenia, with further launches imminent

Malmö, Sweden, and Bad Vilbel, Germany, November 15, 2021, [BIOGLAN](#), the Swedish subsidiary of the Spanish publicly traded pharmaceutical company [REIG JOFRE](#), (BME:RJF), and [STADA Arzneimittel AG](#) have signed an agreement to expand the production capacity for manufacturing a medicine used for the treatment of advanced Parkinson's disease.

Since the launch of the pump-based combination medicine in 2020, Bioglan has already delivered around 250,000 doses via 100 batches, thereby meeting patient need in the initial launch countries. To meet the increasing demand for the therapy as STADA introduces it in further European countries over the coming months, the partners have agreed to build a new factory in Malmö, Sweden. Investment in this expansion that adds a sixth semi-solid production line at the site amounts to more than EUR3 million.

This line will manufacture a patented pharmaceutical gel formulation containing a combination of levodopa/carbidopa and entacapone in a 47ml pre-filled cartridge for continuous infusion into the small intestine through a discreet, lightweight, and wearable pump that weighs 134 grams. The pump is currently prescribed for patients with late-stage Parkinson's disease who are experiencing debilitating motor symptoms that can no longer be controlled by oral medication.

Following initial launches in Nordic countries, the therapy has already been approved in several European countries and is currently marketed by STADA in Germany, Austria and Slovenia, with launches in additional European and selected international markets scheduled in the near future.

Further information

Inma Santa-Pau - Director of Communication and Investor Relations - isantapau@reigjofre.com
www.reigjofre.com



Simon Björklund, CEO of Bioglan, commented: "Our experience in developing and producing semi-solid formulations, usually for topical use, has allowed us in this case, to make available to the market an intra-intestinal gel for continuous infusion. I am pleased to announce that the close and successful collaboration with STADA will allow this expansion and patient access to this therapy."

Robert Wood, managing director of STADA's Britannia Pharmaceuticals subsidiary that specializes in central nervous system disorders such as Parkinson's disease, said the facility expansion reflected the significant potential of this therapy to satisfy unmet patient need for this debilitating condition. "We believe this infusion formulation will have positive clinical benefits for patients who need a device-aided, continuous form of therapy which can resolve intractable motor fluctuations and improve their quality of life. We aim to broaden patient access to a device that is light, user-friendly, and discreet, enabling them to get on with their everyday lives."

REIG JOFRE achieved group sales of 230 million Euros and an EBITDA of 26.5 million Euros in 2020. The *Pharmaceutical Technologies* (antibiotics and injectables), *Specialty Pharmicare* (osteoarticular and dermatology) and *Consumer Healthcare* (food supplements and ENT) units accounted for 48%, 29% and 23%, respectively. REIG JOFRE has direct sales in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, and Singapore), and more than 130 sales partners in more than 70 countries. REIG JOFRE's shares have risen in value 10.44% in the last 5 years.

Further information

Inma Santa-Pau - Director of Communication and Investor Relations - isantapau@reigjofre.com
www.reigjofre.com



About BIOGLAN

Bioglan belongs to the Spanish pharmaceutical company REIG JOFRE and is the center of excellence for semi-solid product development and production. Bioglan offers both development and manufacturing services of pharmaceutical and medical devices. About 100 people work at Bioglan in the site in Malmö, Sweden. REIG JOFRE focus its activity on research, development, manufacture and marketing of pharmaceutical products and food supplements. REIG JOFRE is publicly traded on the Spanish Stock Exchange. For more information, www.bioglan.se.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.

STADA information for journalists:

STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel, Germany
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press
Follow [STADA Group](#) on LinkedIn

STADA information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel, Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations

About REIG JOFRE

Founded in 1929 in Barcelona, REIG JOFRE is a family-run pharmaceutical company, listed on the Spanish stock exchange's continuous market, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements at its four plants in Toledo (2), Barcelona and Malmö (Sweden). REIG JOFRE organizes its product development activities into three business divisions: (1) *Pharmaceutical Technologies* specializing in sterile and lyophilized injectables and penicillin-derived antibiotics; (2) *Specialty Pharmaceutics* specializing in dermatology and osteoarticular disorders; and (3) *Consumer Healthcare* with consumer products under the Forté Pharma brand mostly in France, Belgium, Spain and Portugal, and other OTC areas. REIG JOFRE has more than 1,100 employees, direct sales in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, and Singapore), and more than 130 sales partners in more than 70 countries. REIG JOFRE achieved group sales of €230 million in 2020. REIG JOFRE is listed under the code RJF. Share capital: 77,432,084 shares.

Receive the latest news on the Spanish publicly traded co. REIG JOFRE, by registering at its **subscription centre:** www.reigjofre.com/en/news/subscription-center/

Further information

Inma Santa-Pau - Director of Communication and Investor Relations - isantapau@reigjofre.com
www.reigjofre.com